What is Tirzepatide
Tirzepatide is a dual incretin agonist targeting both GLP-1 and GIP receptors to achieve synergistic metabolic regulation.
Potential Research Effects
• Increased insulin sensitivity and glucose tolerance
• Enhanced fat metabolism and weight loss
• Appetite control and improved energy expenditure
• Reduction in circulating lipid and triglyceride levels
Includes 10 sterile research-use syringes with every vial order.
Cybergen Peptides: Research Use Disclaimer
All products offered by Cybergen Peptides are intended solely for laboratory, educational, and scientific research purposes.
These materials are supplied for in-vitro research only (“in glass”) and are
not intended for human or animal consumption, medical use, or diagnostic applications.
Cybergen Peptides compounds are not drugs, medicines, or dietary supplements and have
not been evaluated or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
They are not intended to diagnose, treat, cure, or prevent any disease.
Any form of bodily introduction, clinical testing, or therapeutic application is strictly prohibited.
